NRXS · Neuraxis, INC

The number of shares of common stock issued as a dividend on the Series B Preferred Stock to Rosalind Master Fund L.P. and the Reporting Person were 221,917 and 12,304, respectively, and was determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock (from the investment date, through the applicable record or conversion date) by $2.38.

Includes (1) 21,598 shares of common stock issued to the Reporting Person as previously disclosed, and (2) 12,304 shares of common stock issued to the Reporting Person as a dividend on the Series B Preferred Stock owned by the Reporting Person.

The number of shares of common stock issued as a dividend on the Series B Preferred Stock to Rosalind Master Fund L.P. and the Reporting Person were 221,917 and 12,304, respectively, and was determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock (from the investment date, through the applicable record or conversion date) by $2.38.

Includes (1) 286,138 shares of common stock purchased by Rosalind Master Fund L.P. in which the Reporting Person has indirect ownership as previously disclosed, and (2) 221,917 shares of common stock issued as a dividend on the Series B Preferred Stock owned by Rosalind Master Fund L.P.

Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein.

Reflects the weighted average price of 40,000 shares of common stock of Neuraxis, Inc. purchased by the reporting person in multiple transactions on February 12, 2026 with purchase prices ranging from $4.70 to $4.95 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Reflects the weighted average price of 40,000 shares of common stock of Neuraxis, Inc. purchased by the reporting person in multiple transactions on February 11, 2026 with purchase prices ranging from $4.53 to $4.85 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

21,598 shares of common stock were issued to the Reporting Person as compensation for services as independent director of the Issuer.

Includes (1) 286,138 shares of common stock owned by Rosalind Master Fund L.P., and (2) 21,598 shares of common stock issued to the Reporting Person as compensation for services as an independent director of the Issuer.

These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

Rosalind Master Fund L.P. purchased 286,138 common shares at $3.52

Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein.

The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.0005 per share of the Issuer's Common Stock.

Reflects the weighted average price of 18,065 shares of common stock of Neuraxis, Inc. purchased by the reporting person in multiple transactions on April 21, 2025 with purchase prices ranging from $1.60 to $1.80 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation for services as independent director of the Issuer. The RSUs will vest in full at the end of 36 months.

These shares of common stock are RSUs granted to the reporting person as the hiring grant. The RSUs will vest in full at the end of 36 months

These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months.

These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months.

These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months.

These shares of common stock are restricted stock units (RSUs) granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months.

These shares of common stock are RSUs granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months.

These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months.

These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months.

These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months.

These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months.

These shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), were issued to Ms. Keyser pursuant to an Unrestricted Stock Award Agreement dated June 28, 2024 (the "Agreement"), by and between NeurAxis, Inc. (the "Company") and Ms. Keyser. Pursuant to the Agreement, as compensation for the services provided as a member of the Board of Directors of the Company by Ms. Keyser through March 31, 2024, the Company issued Ms. Keyser the number of shares of Common Stock as determined by dividing $32,191.78 by the closing price of the Common Stock on June 28, 2024, which was $2.78 per share.

These shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), were issued to Ms. Ferge pursuant to an Unrestricted Stock Award Agreement dated June 28, 2024 (the "Agreement"), by and between NeurAxis, Inc. (the "Company") and Ms. Ferge. Pursuant to the Agreement, as compensation for the services provided as a member of the Board of Directors of the Company by Ms. Ferge through March 31, 2024, the Company issued Ms. Ferge the number of shares of Common Stock as determined by dividing $3,287.67 by the closing price of the Common Stock on June 28, 2024, which was $2.78 per share.

These shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), were issued to Mr. Watkins pursuant to an Unrestricted Stock Award Agreement dated June 28, 2024 (the "Agreement"), by and between NeurAxis, Inc. (the "Company") and Mr. Watkins. Pursuant to the Agreement, as compensation for the services provided as a member of the Board of Directors of the Company by Mr. Watkins through March 31, 2024, the Company issued Mr. Watkins the number of shares of Common Stock as determined by dividing $32,191.78 by the closing price of the Common Stock on June 28, 2024, which was $2.78 per share.

On February 20, 2024, the reporting person received 75,000 shares of common stock of Neuraxis, Inc. pursuant to the terms of a Consulting Agreement dated December 27, 2023.

On February 6, 2024, the reporting person received an aggregate of 150,000 shares of Neuraxis, Inc. (the "Company") common stock from directors and officers of the Company pursuant to the terms of a promissory note dated August 1, 2023.

On December 28, 2023, the reporting person exercised a warrant to purchase 40,000 shares of Neuraxis, Inc. (the "Company") common stock for $0.005 a share. The reporting person paid the exercise price on a cashless basis, resulting in the Company withholding 76 of the warrant shares to pay the exercise price and issuing the reporting person the remaining 39,924 shares.

The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.00005 per share of the Issuer's Common Stock.

Each one share of Series A Preferred Stock converted automatically upon the Issuer's consummation of an initial public offering into two shares of the Issuer's Common Stock. The Series A Preferred Stock had no expiration date.

Each one share of Series A Preferred Stock converted automatically upon the Issuer's consummation of an initial public offering into two shares of the Issuer's Common Stock. The Series A Preferred Stock had no expiration date.